sellWeak cluster of 510b5-1 plan
Allen S. Melemed sold $14k of CMRX
CHIEF MEDICAL OFFICER at CHIMERIX INC. 3,065 shares at an average of $4.50, traded Feb 13, 2025, filed Feb 14, 2025.
Warning score
10Value
$14k
3,065 shares
Holdings after
152,875
-2% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- 0Trade size$14k at market
- 0Share of holdings soldSold 2.0% of holdings
- +15Cluster5 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001415889-25-004219, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 13, 2025 | SOpen-market sale Common Stock10b5-1 | -3,065 | $4.50 | $14k | 152,875 | Feb 14, 2025 |
Related signals
Other insiders at CHIMERIX INC and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 10Weak | CHIMERIX INC | Michael Albert Alrutz SVP AND GENERAL COUNSEL | $7,226 1,600 shares | -1% | |
| 26Weak | CHIMERIX INC | Michael T. Andriole PRESIDENT AND CEO | $33k 7,370 shares | -1% | |
| 17Weak | CHIMERIX INC | Michelle LaSpaluto CHIEF FINANCIAL OFFICER | $10k 2,260 shares | -1% | |
| 10Weak | CHIMERIX INC | David Jakeman VP OF FINANCE AND ACCOUNTING | $1,360 300 shares | -0% | |
| 20Weak | CHIMERIX INC | Michael T. Andriole PRESIDENT AND CEO | $9,636 2,350 shares | -0% | |
| 17Weak | CHIMERIX INC | Michelle LaSpaluto CHIEF FINANCIAL OFFICER | $4,172 1,015 shares | -1% | |
| 10Weak | CHIMERIX INC | David Jakeman VP OF FINANCE AND ACCOUNTING | $11k 2,800 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.